This study is looking at whether a light therapy device called the Anodyne Therapy System can help childhood cancer survivors who have Chemotherapy-Induced Peripheral Neuropathy (CIPN). CIPN is nerve damage caused by chemotherapy, which can lead to pain, numbness, or tingling. The study aims to see if this at-home light therapy is practical and acceptable for survivors to use. You might be able to join if you had cancer as a child (diagnosed before age 21), are currently five years or older, received certain types of chemotherapy, and have CIPN symptoms. The study will be considered successful if at least 70% of participants complete 12 or more light therapy sessions. The current status of this study is unclear, and it plans to enroll 20 participants.

Study design

This is a single-arm pilot study, meaning all 20 participants will receive the light therapy. It is not specified if participants or researchers will be aware of the treatment being given.

What's involved

You would use the Anodyne Therapy System Model 120 at home for 15 minutes per day, 3 days per week, for 6 weeks. Your symptoms will be measured at the beginning and one week after the therapy ends.

Compensation

Not stated in the trial record.

Follow-up

Your neuropathy symptoms will be measured one week after the 6-week intervention is completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.